ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
Annovis Bio, Inc. (NYSE: ANVS) announced an updated webcast and dial-in information for an R&D meeting scheduled on April 20, 2023, at 4:00 PM ET. The webcast aims to review ongoing clinical programs targeting Alzheimer’s disease and Parkinson’s disease. Buntanetap, the company’s lead candidate, is currently in a Phase 3 study for early PD patients and a Phase 2/3 study for mild to moderate AD patients. In previous clinical trials, Buntanetap demonstrated well-tolerated results and significant improvements in motor function for PD patients as well as cognitive enhancement for AD patients. The press release emphasizes the company's focus on addressing neurodegenerative diseases and its commitment to improving patient outcomes.
- Buntanetap has shown statistically significant improvements in motor function in Parkinson's disease patients and cognition in Alzheimer's disease patients during clinical trials.
- Buntanetap met both primary and secondary endpoints in Phase 1/2 studies, demonstrating its effectiveness and safety.
- None.
Company to hold R&D webcast today at 4:00 pm ET to review ongoing clinical programs in Alzheimer's disease and Parkinson's disease
Updated Webcast link and dial-in information are provided below
BERWYN, Penn., April 20, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases is providing an updated link and dial-in information for the Company's R&D Webcast scheduled for today at 4:00 pm ET.
Updated Webcast and dial-in details:
Date: April 20, 2023, 4:00 PM EDT
Participant Toll-Free Dial-In Number: 1 (888) 210-3702
Participant Toll Dial-In Number: 1 (646) 960-0191
Conference ID: 7935665
Webcast Link: https://lifescipartners.zoom.us/webinar/register/WN_N5T1vv09T3CPSkiWlFKIsw
About Buntanetap
Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. In a Phase 1/2 clinical trial in AD and PD patients, buntanetap was shown to be well-tolerated and its pharmacokinetics were found to be in line with levels measured earlier in humans, meeting both the primary and secondary endpoints. Additionally, exploratory endpoints were also met, as treatment with buntanetap resulted in statistically significant improvement in motor function in PD patients and cognition in AD patients. Presently buntanetap is being studied in a Phase 3 study in early PD patients and in a Phase 2/3 study in mild to moderate AD patients.
About Annovis Bio, Inc.
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such AD, PD, and other chronic neurodegenerative diseases. We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein, and has a mechanism of action designed to restore axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD as well as body and brain function associated with PD. Annovis conducted two Phase 1/2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study buntanetap showed improvements in cognition in AD as well as body and function in PD patients.
For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of Buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Media Contact:
Nic Johnson
Russo Partners, LLC
(303) 482-6405
nic.johnson@russopartnersllc.com
Investors Contacts:
Chris Calabrese
+1 (917) 680-5608
ccalabrese@lifesciadvisors.com
LifeSci Advisors, LLC
Kevin Gardner
+1 (617) 283-2856
kgardner@lifesciadvisors.com
LifeSci Advisors, LLC
View original content to download multimedia:https://www.prnewswire.com/news-releases/annovis-bio-provides-updated-webcast-link-and-dial-in-information-for-todays-rd-webcast-301802747.html
SOURCE Annovis Bio
FAQ
What is the purpose of Annovis Bio's R&D webcast on April 20, 2023?
What are the current studies involving Buntanetap by Annovis Bio?
What were the outcomes of the Phase 1/2 clinical trials for Buntanetap?
Where can I find the updated webcast link for Annovis Bio's R&D meeting?
What are the main diseases targeted by Annovis Bio?
